Bayer pulls Dr Reddys in court over generic version of cancer drug Nexavar
Advertisement
New Delhi: Bayer Healthcare LLC and Amgen subsidiary Onyx Pharmaceuticals Inc jointly sued India-based drugmaker Dr. Reddy's Laboratories Inc on Wednesday over its proposed generic version of their cancer drug Nexavar.
Dr. Reddy's filed an Abbreviated New Drug Application (ANDA) for U.S. Food and Drug Administration approval of the generic in May, according to the complaint. An ANDA asserts that the relevant drug patent is invalid or would not be infringed by the generic, and opens the applicant to infringement claims from the patent owner.
For Bayer and Onyx: Bruce Genderson of Williams & Connolly, Jack Blumenfeld of Morris, Nichols, Arsht & Tunnell
Read also: Dr Reddys planning to double OTC products sale through Amazon, others in US
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.